Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EYEGUARD-C gevokizumab in controlled non-infectious intermediate, posterior, or pan-uveitis
2012-001609-25Phase 3Terminated
- Sponsor
- XOMA
- Start
- Dec 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in noninfectious uveitis (NIU), Hyalitis, posterior uveitis and 1 more comparing gevokizumab with placebo (2 arms). Primary endpoint: Proportion of subjects with an occurrence of uveitic disease. Started Dec 2012; status: terminated.
02
Drugs
gevokizumab
03
Conditions
noninfectious uveitis (NIU)Hyalitisposterior uveitispanuveitis
Beyond the preview
Go deeper on 2012-001609-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001609-25.